Identification of genes required for protection from doxorubicin by a genome-wide screen in Saccharomyces cerevisiae

Cancer Research

Volumn 67, Issue 23, 2007, Pages 11411-11418

  Xia, Ling ^a   Jaafar, Lahcen ^a   Cashikar, Anil ^a   Flores Rozas, Hernan ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ADENYLATE KINASE 1; CAMPTOTHECIN; CARRIER PROTEIN; CELL PROTEIN; CISPLATIN; COPPER ZINC SUPEROXIDE DISMUTASE; DAUNORUBICIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE 3; DOXORUBICIN; HYDROXYUREA; MRE11 PROTEIN; NUCLEIC ACID BINDING PROTEIN; PHOSPHOGLUCONATE DEHYDROGENASE; PROTEIN BEM1; PROTEIN BEM4; PROTEIN RAD55; PROTEIN RAD57; PROTEIN RPL37A; PROTEIN SAC7; PROTEIN SER1; PROTEIN SER2; RAD50 PROTEIN; RAD51 PROTEIN; RAD52 PROTEIN; RIBOSOME PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MAC1; TRANSCRIPTION FACTOR UAF30; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ARTICLE; CELL PROTECTION; CELL VIABILITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; GENE DELETION; GENE IDENTIFICATION; HEAT SHOCK RESPONSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; RNA METABOLISM; SACCHAROMYCES CEREVISIAE;

ANTIBIOTICS, ANTINEOPLASTIC; CYTOPROTECTION; DOXORUBICIN; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, NEOPLASM; GENE REGULATORY NETWORKS; GENE SILENCING; GENETIC COMPLEMENTATION TEST; GENOME, FUNGAL; SACCHAROMYCES CEREVISIAE;

EID: 37049036370     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2399     Document Type: Article

References (46)

1. Arcamone F, Cassinelli G, Fantini G, et al. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 1969;11:1101-10.
2. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992;19:670-86.
3. Kaklamani VG, Gradishar WJ. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? Clin Breast Cancer 2003;4 Suppl 1:S26-33.
4. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
5. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-5.
6. Cvetkovic RS, Scott LJ. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 2005;65:1005-24.
7. Boucek RJ, Jr., Olson RD, Brenner DE, Ogunbunmi EM, Inui M, Fleischer S. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem 1987;262:15851-6.
8. Booser DJ, Hortobagyi GN. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 1994;47:223-58.
9. Den Boer ML, Pieters R, Veerman AJ. Mechanisms of cellular anthracycline resistance in childhood acute leukemia. Leukemia 1998;12:1657-70.
10. Gianni L. Anthracycline resistance: the problem and its current definition. Semin Oncol 1997;24:S10-1-S-7.
11. Hudis C. Sequential dose-dense adjuvant therapy with doxorubicin, paclitaxel, and cyclophosphamide. Oncology (Huntingt) 1997;11:15-8.
12. O'Shaughnessy JA, Fisherman JS, Cowan KH. Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. Semin Oncol 1994;21:19-23.
13. Pectasides D, Psyrri A, Pectasides M, Economopoulos T. Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan? Expert Opin Pharmacother 2006;7:975-87.
14. Valero V, Perez E, Dieras V. Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects. Semin Oncol 2001;28:15-23.
15. Durant ST, Morris MM, Illand M, et al. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr Biol 1999;9:51-4.
16. Fedier A, Schwarz VA, Walt H, Carpini RD, Haller U, Fink D. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer 2001;93:571-6.
17. Winzeler EA, Shoemaker DD, Astromoff A, et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 1999;285:901-6.
18. 1 and S phases is CCR4 dependent following ionizing radiation or replication stress in Saccharomyces cerevisiae. Eukaryot Cell 2004;3:430-46.
19. Huang RY, Eddy M, Vujcic M, Kowalski D. Genomewide screen identifies genes whose inactivation confer resistance to cisplatin in Saccharomyces cerevisiae. Cancer Res 2005;65:5890-7.
20. Alani E, Reenan RA, Kolodner RD. Interaction between mismatch repair and genetic recombination in Saccharomyces cerevisiae. Genetics 1994;137:19-39.
21. Tishkoff DX, Filosi N, Gaida GM, Kolodner RD. A novel mutation avoidance mechanism dependent on S. cerevisiae RAD27 is distinct from DNA mismatch repair. Cell 1997;88:253-63.
22. Huang RY, Kowalski D, Minderman H, Gandhi N, Johnson ES. Small ubiquitin-related modifier pathway is a major determinant of doxorubicin cytotoxicity in Saccharomyces cerevisiae. Cancer Res 2007;67:765-72.
23. Macris MA, Sung P. Multifaceted role of the Saccharomyces cerevisiae Srs2 helicase in homologous recombination regulation. Biochem Soc Trans 2005;33:1447-50.
24. Watts FZ. Sumoylation of PCNA: wrestling with recombination at stalled replication forks. DNA Repair (Amst) 2006;5:399-403.
25. Roberts CW, Orkin SH. The SWI/SNF complex-chromatin and cancer. Nat Rev Cancer 2004;4:133-42.
26. Romeo MJ, Angus-Hill ML, Sobering AK, Kamada Y, Cairns BR, Levin DE. HTL1 encodes a novel factor that interacts with the RSC chromatin remodeling complex in Saccharomyces cerevisiae. Mol Cell Biol 2002;22:8165-74.
27. Shen X, Ranallo R, Choi E, Wu C. Involvement of actin-related proteins in ATP-dependent chromatin remodeling. Mol Cell 2003;12:147-55.
28. Horiuchi J, Silverman N, Pina B, Marcus GA, Guarente L. ADA1, a novel component of the ADA/GCN5 complex, has broader effects than GCN5, ADA2, or ADA3. Mol Cell Biol 1997;17:3220-8.
29. Siddiqi IN, Dodd JA, Vu L, et al. Transcription of chromosomal rRNA genes by both RNA polymerase I and II in yeast uaf30 mutants lacking the 30 kDa subunit of transcription factor UAF. EMBO J 2001;20:4512-21.
30. Tyler JK, Adams CR, Chen SR, Kobayashi R, Kamakaka RT, Kadonaga JT. The RCAF complex mediates chromatin assembly during DNA replication and repair. Nature 1999;402:555-60.
31. Meneghini MD, Wu M, Madhani HD. Conserved histone variant H2A Z protects euchromatin from the ectopic spread of silent heterochromatin. Cell 2003;112:725-36.
32. Driscoll R, Hudson A, Jackson SP. Yeast Rtt109 promotes genome stability by acetylating histone H3 on lysine 56. Science 2007;315:649-52.
33. Walsh P, Bursac D, Law YC, Cyr D, Lithgow T. The J-protein family: modulating protein assembly, disassembly and translocation. EMBO Rep 2004;5:567-71.
34. Osherovich LZ, Weissman JS. Multiple Gln/Asn-rich prion domains confer susceptibility to induction of the yeast [PSI(+)] prion. Cell 2001;106:183-94.
35. Kang CM, Jiang YW. Genome-wide survey of non-essential genes required for slowed DNA synthesis-induced filamentous growth in yeast. Yeast 2005;22:79-90.
36. Chi NW, Kolodner RD. Purification and characterization of MSH1, a yeast mitochondrial protein that binds to DNA mismatches. J Biol Chem 1994;269:29984-92.
37. Roeder AD, Hermann GJ, Keegan BR, Thatcher SA, Shaw JM. Mitochondrial inheritance is delayed in Saccharomyces cerevisiae cells lacking the serine/threonine phosphatase PTC1. Mol Biol Cell 1998;9:917-30.
38. Breitkreutz BJ, Stark C, Tyers M. Osprey: a network visualization system. Genome Biol 2003;4:R22.
39. Ross WE, Bradley MO. DNA double-stranded breaks in mammalian cells after exposure to intercalating agents. Biochim Biophys Acta 1981;654:129-34.
40. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984;226:466-8.
41. Demidenko ZN, Vivo C, Halicka HD, et al. Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor-and cycle-arrest-mediated cytoprotection. Cell Death Differ 2006;13:1434-41.
42. Hansen RK, Parra I, Lemieux P, Oesterreich S, Hilsenbeck SG, Fuqua SA. Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat 1999;56:187-96.
43. Drysdale MJ, Brough PA, Massey A, Jensen MR, Schoepfer J. Targeting Hsp90 for the treatment of cancer. Curr Opin Drug Discov Devel 2006;9:483-95.
44. Eisenman HC, Craig EA. Activation of pleiotropic drug resistance by the J-protein and Hsp70-related proteins, Zuo1 and Ssz1. Mol Microbiol 2004;53:335-44.
45. Arevalo-Rodriguez M, Pan X, Boeke JD, Heitman J. FKBP12 controls aspartate pathway flux in Saccharomyces cerevisiae to prevent toxic intermediate accumulation. Eukaryot Cell 2004;3:1287-96.
46. Waddell WJ. Thresholds of carcinogenicity of flavors. Toxicol Sci 2002;68:275-9.